Cefprozil
From Wikipedia, the free encyclopedia
|
Cefprozil
|
|
| Systematic (IUPAC) name | |
| 8-[2-amino-2-(4-hydroxyphenyl)-acetyl] amino-7-oxo-4-prop-1-enyl-2-thia-6- azabicyclo [ 4.2.0]oct-4-ene-5-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H19N3O5S |
| Mol. mass | 389.427 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 36% |
| Metabolism | ? |
| Half life | 1.3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
Category-B |
| Legal status | |
| Routes | ORAL |
Cefprozil, sometimes spelled cefproxil and sold under the brand name Cefzil, is a cephalosporin type antibiotic. In Europe, it is sold by the name Procef. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. It comes as a tablet and as a liquid suspension.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006)[1] has shown no increased risk for cross-allergy for cefprozil and several other 2nd generation or later cephalosporins.
[edit] References
[edit] External links
|
||||||||||||||||||||

